Leqembi Launched in China to Fight Alzheimer’s

The launch of LEQEMBI in China marks an important milestone in the fight against Alzheimer’s disease. 

With a high prevalence of the disease in the country, this innovative treatment option brings hope to millions of patients and their families who have been desperately seeking effective therapies¹.

LEQEMBI, also known as Lecanemab, is a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody. It selectively binds to both soluble Aβ aggregates (protofibrils) and insoluble Aβ aggregates (fibrils), reducing Aβ plaques in the brain. 

Notably, LEQEMBI is the world’s first approved treatment shown to slow cognitive and functional decline in Alzheimer’s patients through this mechanism².

Its launch in China provides a crucial opportunity for early detection, diagnosis, and treatment, supporting those affected to “live their fullest lives.

The post Leqembi Launched in China to Fight Alzheimer’s appeared first on Alzheimer's & Dementia Weekly.